VCU research shows erectile dysfunction drug reduces death of heart cells in heart attack model

RICHMOND, Va. (Jan. 31, 2005) Virginia Commonwealth University researchers have shown that a widely used drug for treating erectile dysfunction, Viagra, reduces the death of heart cells under heart attack-like conditions in a laboratory model.

The results are a key finding that may help researchers develop a new treatment for patients with heart failure where the loss of cells is primarily due to cell suicide.

In the Journal of Biological Chemistry, published online Jan. 24, VCU researchers found that treatment with Viagra, generically known as sildenafil citrate, at clinically relevant concentrations produced therapeutic levels of nitric oxide (NO) in the heart cells of mice by increasing protein levels of two enzymes responsible for the synthesis of NO.

Employing a cellular model where heart attack-like conditions are simulated in a Petri dish, they demonstrated that NO produced from sildenafil inhibits cell death by stabilizing mitochondria, increasing the level of the anti-death protein, Bcl-2, and inhibiting caspase 3, the protein considered to be the ultimate weapon in cell suicide.

"This research has established a strong basis for the design of future studies targeted toward investigating the clinical effects of sildenafil on survival of heart muscle following a major heart attack," said Rakesh C. Kukreja, Ph.D., professor of medicine, physiology and biochemistry at VCU, and lead author of the study.

"In addition, these findings suggest that this drug may slow or possibly reverse the progressive loss of heart cells during chronic heart failure in patients with coronary artery disease," he said.

Researchers used heart cells prepared from genetically engineered mice that lack nitric oxide synthesizing enzymes. The model was particularly useful in studying the protective effect of sildenafil in heart muscle cells independent of any vascular effects or other types of cells, Kukreja said.

According to Kukr

Contact: Sathya Achia-Abraham
Virginia Commonwealth University

Page: 1 2

Related biology news :

1. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
2. Saudi Arabias KAUST names WHOI first research partner
3. Multinational research: protecting ecology means understanding people, too
4. Newly created cancer stem cells could aid breast cancer research
5. Carnegie Mellons Peter Adams receives EPA research grant
6. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
7. Innovative tagging technique may help researchers better protect fish stocks
8. Penn researchers discover how key protein stops inflammation
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. ASU researchers partner with UOP to make biofuel for military jets a reality
11. Einstein researchers prototype vaccine could provide improved protection against tuberculosis

Post Your Comments:

(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
Breaking Biology Technology:
Cached News: